- Report
- August 2022
Global
From €1048EUR$1,090USD£898GBP
- Report
- February 2021
Global
From €2845EUR$2,960USD£2,440GBP
- Report
- January 2022
- 160 Pages
Global
From €10568EUR$10,995USD£9,062GBP
- Report
- November 2022
- 68 Pages
Global
From €3359EUR$3,495USD£2,881GBP
- Report
- December 2021
- 52 Pages
Global
From €3840EUR$3,995USD£3,293GBP
- Report
- December 2018
- 48 Pages
Global
From €3359EUR$3,495USD£2,881GBP
- Drug Pipelines
- September 2020
- 385 Pages
Global
From €1922EUR$2,000USD£1,648GBP
- Report
- November 2020
- 199 Pages
Global
€4325EUR$4,500USD£3,709GBP
- Report
- October 2018
- 104 Pages
Global
From €2643EUR$2,750USD£2,267GBP
- Report
- October 2023
- 134 Pages
Global
From €3500EUR$3,901USD£3,106GBP
- Report
- October 2023
- 88 Pages
Global
From €3500EUR$3,901USD£3,106GBP
- Report
- February 2024
- 79 Pages
Global
From €3500EUR$3,901USD£3,106GBP
- Report
- November 2023
- 113 Pages
Global
From €3500EUR$3,901USD£3,106GBP
- Report
- June 2022
- 347 Pages
Global
From €2403EUR$2,500USD£2,061GBP
- Report
- May 2022
- 81 Pages
Global
From €1922EUR$2,000USD£1,648GBP
- Report
- May 2023
- 160 Pages
Global
From €5766EUR$5,999USD£4,945GBP
The Glaucoma Drug market is a subset of the Optical Disorders Drugs market, which includes medications used to treat a variety of eye conditions. Glaucoma is a group of eye diseases that cause damage to the optic nerve, resulting in vision loss. Glaucoma drugs are used to reduce intraocular pressure, which is the main risk factor for glaucoma. These drugs can be administered orally, topically, or through injections. Commonly used glaucoma drugs include prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors, and cholinergic agonists.
Some of the major companies in the Glaucoma Drug market include Allergan, Pfizer, Merck, Novartis, Bausch Health, Sun Pharmaceuticals, Santen Pharmaceuticals, and Alcon. Show Less Read more